论文部分内容阅读
恶性胸腔积液是进展期恶性肿瘤的常见并发症,严重影响患者生存期及生活质量。药物胸腔内局部灌注是目前临床常用的治疗手段,文章从胸膜硬化剂、化疗药物、生物免疫制剂、中药制剂等研究进展入手,对不同药物治疗本病的适宜人群及优劣势等方面进行比较分析。认为近年来本病治疗研究虽在系统评价、疗效指标、动物实验及药学方面取得了突破,药物种类及联合用药报道逐年增多,但针对本病干预机制、联合用药及个体化用药、最佳治疗手段标准制定、中西医协同干预等领域尚需进一步研究。
Malignant pleural effusion is a common complication of advanced malignant tumors, seriously affecting the patient’s survival and quality of life. The local intrathoracic perfusion of drug is the commonly used clinical treatment method at present. This article starts with the research progress of pleural sclerotherapy, chemotherapy drugs, biological immune preparations and traditional Chinese medicine preparations, and compares and analyzes the appropriate groups, advantages and disadvantages of different drugs in treating this disease. . It is considered that the treatment of this disease has made breakthroughs in the aspects of systematic evaluation, curative index, animal experiment and pharmacy in recent years. The types of drugs and the combination of drugs have been increasing year by year. However, according to the intervention mechanism of the disease, combination therapy and individualized medication, the best treatment Means standard-setting, Integrative Medicine and other fields need further study.